CD274 and cancer: The recent introduction of monoclonal antibodies (mAbs) targeting the PD-1/PD-L1 signaling axis in cancer therapy significantly improved the survival of patients with different advanced and aggressive tumor types, including melanoma, non-small-cell lung cancer, and kidney carcinoma [49].